HOME >> MEDICINE >> NEWS
New compound unusually potent at blocking brain cancer growth

By determining how a class of compounds blocks signaling in cells, UCSF scientists have identified what is perhaps the most potent drug candidate yet against a highly lethal kind of brain tumor.

The compound, known as PI-103, shows unique potency against cancer cell proliferation in studies of mice with grafts of human glioma cells. Gliomas are the most common form of brain cancer, and have proven very difficult to treat.

The unique effectiveness of PI-103 stems from its ability to attack two separate steps in the series of signals that trigger the spread of cancer. The dual blockade proved to be a safe and effective inhibitor of cancer cell proliferation in mice with the human tumors, the scientists found.

The glioma research is being published online May 15 by the journal Cancer Cell. A description of the strategy used to identify the molecular level action of the inhibitors was published online by the journal Cell on April 27.

Food and Drug Administration approval five years ago of the cancer drug Gleevec marked a promising new strategy against cancer. Gleevec was the first drug on the market designed to block ubiquitous signaling molecules called protein kinases enzymes known to trigger normal cell proliferation, and in the case of cancer, the growth of tumors. Another group of kinases, called lipid kinases are now emerging as important new targets, especially PI3 alpha kinase, an enzyme often found to be overactive in brain, breast, colon and stomach cancers.

But the sheer number of related kinases 15 in the PI3 kinase family alone and uncertainty about how each acts in the body has stalled progress. Broad spectrum drugs that inhibit many related kinases inevitably cause toxicity and are poor drug candidates.

To overcome this hurdle, Kevan Shokat, PhD, a Howard Hughes Medical Institute investigator at UCSF, and Zachary Knight, a postdoctoral fellow in his lab, developed a strategy to systematically inhibit many different but r
'"/>

Contact: Wallace Ravven
wravven@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
15-May-2006


Page: 1 2 3

Related medicine news :

1. New oxidation methods streamline synthesis of important compounds
2. AMPAKINE compounds a new potential treatment for respiratory depression
3. Green tea compound suppresses factors causing cartilage, bone destruction in arthritis
4. Green tea compound may be a therapy for people with rheumatoid arthritis
5. Anti-dandruff compound may help fight epilepsy
6. Depression among retired NFL players: Rates mirror the general public, but pain compounds symptoms
7. Chromium 6: A killer compound with an improbable trigger
8. New compound shows promise in halting HIV spread
9. New imaging compound might see Alzheimers earlier
10. U of M researchers discover compounds to shrink tumors
11. Diagnosis and treatment of osteoporosis falls shortnon adherence compounds issue

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/23/2017)... New York (PRWEB) , ... August 23, 2017 , ... ... intellectual and developmental disabilities (I/DD), has launched a groundbreaking LGBTQ community organization for people ... just the first organization of its kind in the state of New Jersey – ...
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... Jachimowicz ... California, office at 1530 The Alameda, Suite 115. The office is located between Schiele ... the contact information remains the same. Clients can still call the office at 408-246-5500. ...
(Date:8/23/2017)... Texas (PRWEB) , ... August 23, 2017 , ... This ... denied claims firms in Texas. Founded by Bill Voss, the firm grew quickly and ... decade and a half of helping clients get the money they deserve from their ...
(Date:8/23/2017)... ... 2017 , ... Loyale Healthcare today announced the ... joins other recent high-profile hires including Frank Massi, Chief Revenue Officer and Shirley ... helping physician practices and hospitals automate their clinical and financial processes to gain ...
(Date:8/23/2017)... ... 2017 , ... Drs. Steven White and Brad Haines are pleased to announce ... of this offer, valued at more than $300 per year, new patients can enjoy ... patients receive a complimentary professional whitening procedure. , Stained or yellowed tooth enamel ...
Breaking Medicine News(10 mins):
(Date:8/23/2017)... 23, 2017 DarioHealth Corp. (NASDAQ: DRIO), ... health and big data solutions, announced today that ... with domestic and non-U.S. investors for the sale ... shares of the Company,s newly designated Series B ... Current shareholders accounted for 58% of the securities ...
(Date:8/23/2017)... -- Epygenix Therapeutics, Inc., a privately held biopharmaceutical company developing ... epilepsy, announced today that the U.S. Food and Drug ... the treatment of patients with Dravet Syndrome. Dravet Syndrome ... of the Food, Drug, and Cosmetic Act. ... of epilepsy, begins in the first year of life ...
(Date:8/18/2017)... , Aug. 18, 2017  Nortis today announced the awarding of a $688K ... for the third year of a Small Business Innovation ... Institute of Neurological Disorders and Stroke (NINDS).?  ... Nortis ParVivo Chip ... ...
Breaking Medicine Technology:
Cached News: